05.06.2015 13:17:28
|
Bayer To Pay Isis Immediate $100 Mln Up-front Payment - Quick Facts
(RTTNews) - Isis Pharmaceuticals, Inc. (ISIS) announced that its license agreement with Bayer HealthCare to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Based on the approval, Bayer will pay Isis an immediate $100 million up-front payment.
In total, Isis is eligible to receive up to $375 million in payments, including the upfront payment and a $55 million near-term milestone payment upon advancement of the program following the Phase 2 study in patients with compromised kidney function. Isis is also eligible to receive tiered royalties in the low to high twenty percent range on gross margins of ISIS-FXIRx.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu ISIS Pharmaceuticals Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |